ALNY » Topics » Revenues

This excerpt taken from the ALNY 8-K filed Feb 25, 2010.

Revenues

Revenues were $26.6 million for the fourth quarter of 2009, as compared to $24.4 million for the same period last year. Revenues for the fourth quarter of 2009 included $15.2 million of collaboration revenues related to the company’s alliance with Roche, $5.5 million of revenues from the company’s alliance with Takeda Pharmaceuticals Company Limited, which began in the second quarter of 2008, and $5.9 million of expense reimbursement and amortization revenues from Novartis, the National Institutes of Health (NIH), Cubist Pharmaceuticals, Inc., Biogen Idec Inc., InterfeRx™, research reagent and services licenses, and other sources. Revenues were $100.5 million for the year ended December 31, 2009, as compared to $96.2 million for the prior year. Revenues increased for the year ended December 31, 2009 as compared to the year ended December 31, 2008 primarily as a result of a full year of GAAP revenues earned from the company’s May 2008 alliance with Takeda. Revenues for the year ended December 31, 2009 included $56.9 million of collaboration revenues related to the company’s alliance with Roche, $21.7 million of revenues related to the company’s collaboration with Takeda, and $21.9 million of revenues related to the company’s collaborations with Novartis, the NIH, Cubist, Biogen Idec, InterfeRx, research reagent and services licenses, and other sources.

This excerpt taken from the ALNY 8-K filed Nov 4, 2009.

Revenues

Revenues were $24.2 million for the third quarter of 2009, as compared to $25.7 million for the same period last year. Revenues for the third quarter of 2009 included $13.8 million of collaboration revenues related to the company’s alliance with Roche, $5.4 million of revenues from the company’s alliance with Takeda Pharmaceutical Company Limited, and $5.0 million of expense reimbursement and amortization revenues from Novartis, the National Institutes of Health (NIH), Cubist Pharmaceuticals, Inc., Biogen Idec Inc., InterfeRx™, research reagent and services licensees, and other sources.

This excerpt taken from the ALNY 8-K filed Aug 6, 2009.

Revenues

Revenues were $24.6 million for the second quarter of 2009, as compared to $23.8 million for the same period last year. The increase in revenues for the second quarter of 2009 as compared to the prior year period was primarily related to $5.4 million of revenues from the company’s alliance with Takeda Pharmaceutical Company Limited, which began in May of 2008. Also included in revenues were $14.0 million of collaboration revenues related to the company’s alliance with Roche and $5.2 million of expense reimbursement and amortization revenues from Novartis, the National Institutes of Health (NIH), Cubist Pharmaceuticals, Inc., Biogen Idec, InterfeRx™, research reagent and services licensees, and other sources.

This excerpt taken from the ALNY 8-K filed May 7, 2009.

Revenues

Revenues were $25.1 million for the first quarter of 2009, as compared to $22.2 million for the same period last year. The increase in revenues for the first quarter of 2009 as compared to the prior year period, was primarily related to $5.4 million of revenues from the company’s alliance with Takeda Pharmaceutical Company Limited, which began in the second quarter of 2008. Also included in revenues were $13.8 million of net collaboration revenues related to the company’s alliance with Roche, which began in the third quarter of 2007, and $5.9 million of expense reimbursement and amortization revenues from Novartis, the National Institutes of Health (NIH), Cubist Pharmaceuticals, Inc., Biogen Idec, InterfeRx™, research reagent and services licensees, and other sources.

This excerpt taken from the ALNY 8-K filed Feb 24, 2009.

Revenues

Revenues in the fourth quarter of 2008 were $24.4 million, as compared to $18.2 million for the same period last year. Revenues for the fourth quarter of 2008 included $14.0 million of net collaboration revenues related to the company’s alliance with Roche, which began in the third quarter of 2007, as well as $5.4 million of revenues from the company’s alliance with Takeda Pharmaceuticals Company Limited, which began in the second quarter of 2008. Revenues from the fourth quarter also included $5.0 million of expense reimbursement and amortization revenues from Novartis, the National Institutes of Health (NIH), the Department of Defense (DOD), Biogen Idec, InterfeRx™, research reagent and services licensees, and other sources. Revenues for the full year ended December 31, 2008 were $96.2 million as compared to $50.9 million for the prior year. Revenues increased significantly for the year ended December 31, 2008 as compared to the year ended December 31, 2007 primarily as a result of the GAAP revenues earned from the company’s August 2007 alliance with Roche, as well as the company’s May 2008 alliance with Takeda. Revenues for the year ended December 31, 2008 included $54.4 million of net collaboration revenues related to the company’s alliance with Roche, $12.8 million of revenues related to the company’s collaboration with Takeda, and $29.0 million of revenues related to the company’s collaborations with Novartis, the NIH, the DOD, Biogen Idec, InterfeRx, research reagent and services licensees, and other sources.


This excerpt taken from the ALNY 8-K filed Nov 5, 2008.

Revenues

Revenues in the third quarter of 2008 were $25.7 million, as compared to $16.3 million in the third quarter of 2007. The significant increase in revenues in the third quarter of 2008 was primarily related to $13.7 million of net collaboration revenues related to the company’s alliance with Roche, which began in the third quarter of 2007, as well as $5.4 million of revenues from the company’s alliance with Takeda, which began in the second quarter of 2008. Revenues in the third quarter of 2008 also included $6.6 million of expense reimbursement and amortization revenues from Novartis, the National Institutes of Health (NIH), the Department of Defense (DOD), Biogen Idec, InterfeRx™, research reagent and services licensees, and other sources.

This excerpt taken from the ALNY 8-K filed Aug 6, 2008.

Revenues

Revenues in the second quarter of 2008 were $23.8 million, compared to $9.1 million in the second quarter of 2007. The significant increase in revenues in the second quarter of 2008 was primarily related to $13.4 million of net collaboration revenues related to the company’s alliance with Roche, which began in the third quarter of 2007. Revenues for the second quarter of 2008 also included $10.4 million of expense reimbursement and amortization revenues from Novartis, Takeda Pharmaceutical Company Limited, the National Institutes of Health (NIH), the Department of Defense (DOD), Biogen Idec, InterfeRx™, research reagent and services licensees, and other sources.

This excerpt taken from the ALNY 8-K filed May 8, 2008.

Revenues

Revenues in the first quarter of 2008 were $22.2 million, compared to $7.2 million during the first quarter of 2007. The significant increase in revenues in the first quarter of 2008 was primarily related to $13.4 million of net collaboration revenues related to the company’s alliance with Roche, which began in the third quarter of 2007. Revenues for the first quarter of 2008 also included $8.8 million of expense reimbursement and amortization revenues from Novartis, the National Institutes of Health (NIH), the Department of Defense (DOD), Biogen Idec, InterfeRx™, research reagent and services licensees, and other sources.

This excerpt taken from the ALNY 8-K filed Feb 7, 2008.

Revenues

Revenues in the fourth quarter of 2007 were $18.2 million, as compared to $7.0 million for the same period last year. Revenues for the fourth quarter of 2007 included $11.2 million of net collaboration revenues related to the company’s alliance with Roche and $7.0 million of revenues from Novartis, the National Institutes of Health (NIH), the Department of Defense (DOD), Biogen Idec, InterfeRx™, research reagent and services licensees, and other sources. Revenues for the full year ended December 31, 2007 were $50.9 million as compared to $26.9 million for the prior year. Revenues for the year ended December 31, 2007 included $17.6 million of net collaboration revenues related to the company’s alliance with Roche, $14.7 million of revenues related to the company’s collaborations with Novartis, and $18.6 million of revenues from Biogen Idec, the NIH, the DOD, InterfeRx, research reagent and services licensees, and other sources.

This excerpt taken from the ALNY 10-K filed Mar 16, 2006.
Revenues
 
The following table summarizes the payments received by us under our strategic research collaboration agreements with Merck as well as our total consolidated revenues in the periods indicated, in thousands:
 
                 
    Year Ended December 31,  
    2004     2003  
 
Net revenues recorded from collaboration agreements with Merck
  $ 4,066     $ 111  
Other revenues
    212       65  
                 
Total revenues recorded
  $ 4,278     $ 176  
                 
 
We received a $2.0 million license fee from our first agreement with Merck in September 2003, which has been deferred and is being recognized as revenue over six years, the estimated period of performance under the collaboration agreement. In September 2004, we received an additional license fee of $1.0 million from Merck related to this agreement. We recognized revenues of $0.6 million and $0.1 million from the amortization of these payments in 2004 and 2003, respectively. The increase in these revenues is due to a full year of amortization of the payment received in September 2003 and the amortization of the additional payment received in September 2004.


59


Table of Contents

In December 2004, we achieved a scientific milestone, as defined by this agreement, resulting in a $2.0 million milestone payment from Merck. In connection with the achievement of this scientific milestone, Merck made a $5.0 million equity investment in our common stock. The purchase price of this common stock, as defined by the agreement, was determined based on the average trading price of our common stock during the twenty days prior to the purchase, which was $7.04. The price of our common stock on the date of the purchase was $7.40 and resulted in an actual value of $5.3 million for the common stock issued to Merck. As a result, we recorded a reduction of $0.3 million to the revenue recorded from Merck.
 
In June 2004, we entered into an additional collaboration and license agreement with Merck for the co-development of RNAi therapeutics for the treatment of ocular diseases. Under the terms of the agreement, we received a $2.0 million license fee from Merck as well as $1.0 million representing reimbursement of prior research and development costs which we incurred on our AMD program targeting vascular endothelial growth factor, or VEGF. These amounts are being amortized into revenues over the estimated period of performance under the collaboration agreement of six years. As such, we recorded $0.2 million of revenues in 2004 from the amortization of these payments. In addition to up-front and milestone payments, our collaboration agreement with Merck related to RNAi therapeutics for ocular diseases provides for the sharing of costs incurred under this agreement. In 2004, we recorded net revenues of $1.5 million from these cost sharing activities related to the AMD program.
 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki